J. Safra Sarasin Holding AG decreased its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 22.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,962 shares of the company's stock after selling 6,238 shares during the period. J. Safra Sarasin Holding AG's holdings in DaVita were worth $3,360,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also bought and sold shares of DVA. Epoch Investment Partners Inc. acquired a new position in shares of DaVita during the fourth quarter valued at about $55,100,000. Invesco Ltd. lifted its stake in DaVita by 20.9% in the fourth quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock valued at $237,716,000 after buying an additional 275,284 shares during the last quarter. Iron Triangle Partners LP acquired a new position in DaVita during the fourth quarter worth $38,946,000. GAMMA Investing LLC boosted its stake in DaVita by 14,695.8% in the 1st quarter. GAMMA Investing LLC now owns 234,809 shares of the company's stock worth $35,919,000 after buying an additional 233,222 shares during the last quarter. Finally, Bridgewater Associates LP grew its stake in shares of DaVita by 298.4% in the fourth quarter. Bridgewater Associates LP now owns 239,970 shares of the company's stock valued at $35,888,000 after buying an additional 179,744 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.
Insider Buying and Selling
In related news, insider James O. Hearty sold 2,351 shares of the company's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $150.00, for a total transaction of $352,650.00. Following the completion of the transaction, the insider directly owned 26,038 shares in the company, valued at $3,905,700. This represents a 8.28% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.00% of the stock is owned by company insiders.
DaVita Price Performance
DVA stock traded up $1.10 during trading on Tuesday, hitting $140.62. 174,320 shares of the company's stock traded hands, compared to its average volume of 846,097. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.20 and a current ratio of 1.25. The stock has a market capitalization of $10.62 billion, a price-to-earnings ratio of 13.92, a P/E/G ratio of 0.96 and a beta of 1.09. The business has a fifty day simple moving average of $140.47 and a 200 day simple moving average of $147.52. DaVita Inc. has a 52 week low of $131.76 and a 52 week high of $179.60.
DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported $2.00 EPS for the quarter, beating analysts' consensus estimates of $1.75 by $0.25. The company had revenue of $3.22 billion for the quarter, compared to analysts' expectations of $3.22 billion. DaVita had a net margin of 6.63% and a return on equity of 176.11%. DaVita's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.26 earnings per share. As a group, research analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of brokerages have weighed in on DVA. Wall Street Zen raised DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Truist Financial decreased their price objective on DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a research report on Monday, May 19th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $167.40.
Check Out Our Latest Stock Report on DaVita
About DaVita
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Further Reading
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
